网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
晚期非鳞非小细胞肺癌外周血EGFR基因应用研究
作者:赵鹏  严明基  刘学敏  陈玮 
单位:云浮市人民医院肿瘤科, 广东 云浮 527300
关键词:非小细胞肺癌 扩增受阻突变系统 表皮生长因子受体 易瑞沙 
分类号:R734.2
出版年·卷·期(页码):2019·47·第二期(161-164)
摘要:

目的:探讨非鳞非小细胞肺癌患者外周血表皮生长因子受体(EGFR)基因突变与易瑞沙治疗疗效的相关性。方法:采用突变扩增系统-聚合酶链式反应(ARMS-PCR)检测60例非鳞非小细胞肺癌患者外周血EGFR基因多态性,对其中27例进行肿瘤组织EGFR检测与外周血检测结果的一致性比较,并进行疗效评价和相关性分析。结果:患者临床资料与EGFR基因突变无显著相关性(P>0.05)。EGFR基因突变患者的缓解率和控制率均显著高于野生型(P<0.05)。生存曲线显示外周血EGFR基因突变组无进展生存期显著长于野生型(P<0.05)。配对检测显示,外周血与肿瘤组织的EGFR基因突变一致率为51.9%(14/27)。结论:非鳞非小细胞肺癌患者外周血EGFR基因多态性与易瑞沙治疗疗效之间具有相关性,外周血EGFR基因突变患者的易瑞沙治疗疗效更好,具有临床应用价值。

Objective:To investigate the mutation rate of epidermal growth factor receptor(EGFR) in non-squamous non-small cell lung cancer patients and their correlation with Erisha clinical efficacy.Methods:The ARMS-PCR method was used to detect the EGFR mutation of peripheral blood in 60 patients with non-small cell lung cancer, of which 27 cases were compared with the results of peripheral blood detection ofEGFR. The effect was evaluated and the correlation was analyzed.Results:There was no significant correlation between the clinical data and EGFR mutation(P>0.05). The remission rate and control rate of patients with EGFR mutation were significantly higher than those of wild type(P<0.05). Survival curves showed that the progression free survival time of peripheral blood EGFR mutant group was significantly longer than that of wild type(P<0.05). Paired detection showed that the coincidence rate of EGFR mutation in peripheral blood and tumor tissues was 51.9%(14/27).Conclusion:The polymorphisms of EGFR gene in peripheral blood of patients with non-squamous non-small cell lung cancer were correlated with the therapeutic efficacy of Erisha. The patients with EGFR gene mutation in peripheral blood had better therapeutic effect and had clinical application value.

参考文献:

[1] ZAPPA C,MOUSA S A.Non-small cell lung cancer:current treatment and future advances[J].Transl Lung Cancer Res,2016,5(3):288-300.
[2] 乐胜兵,吴密璐.非小细胞肺癌靶向治疗研究进展[J].现代肿瘤医学,2016,24(5):840-843.
[3] 陆舜,虞永峰,纪文翔.2015年肺癌诊疗指南:共识和争议[J].解放军医学杂志,2016,41(1):1-6.
[4] TENG F,LIU M,CUI G,et al.Clinical efficacy of iressa combined with radiotherapy in treatment of patients with non-small cell lung cancer and brain metastasis[J].J Clin Med Pract,2017,13(5):381-382.
[5] HIRSCH F R,SEQUIST L V,GORE I,et al.Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer:Results from the US IRESSA clinical access program(ICAP)[J].Cancer,2018,124(11):2407-2414.
[6] WERNER L,KELLER F A,BHURE U,et al.The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography(FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancer[J].BMC Med Imaging,2017,17(1):41.
[7] NORMANNO N,DENIS M G,THRESS K S,et al.Guide to detecting epidermal growth factor receptor(EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer[J].Oncotarget,2017,8(7):12501-12506.
[8] TALSMA K,HAGEN P V,GROTENHUIS B A,et al.Comparison of the 6th and 7th editions of the UICC-AJCC TNM classification for esophageal cancer[J].Ann Surg Oncol,2012,19(7):2142-2148.
[9] ZHANG Q,ZHANG X,YAN H,et al.Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone onEGFR-mutant non-small cell lung cancer with brain metastasis[J].Thorac Cancer,2016,7(6):648-654.
[10] 张卉,张树才.非小细胞肺癌EGFR基因靶向治疗研究进展[J].中国肺癌杂志,2017,20(1):61-65.
[11] 邵慧,陈愉生,李鸿茹,等.晚期肺腺癌EGFR-TKIs靶向治疗临床疗效的研究[J].肿瘤学杂志,2016,22(8):627-631.
[12] 马玲,张琰,单莉,等.维吾尔族晚期非小细胞肺癌患者EGFR、KRAS基因突变状态及其与TKI靶向治疗效果的关系[J].山东医药,2016,56(31):66-68.
[13] SHODA K,ICHIKAWA D,FUJITA Y,et al.Monitoring the HER2,copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer[J].Gastric Cancer,2016,20(1):1-10.
[14] BRYCHTA N,KRAHN T,VON A O.Detection of KRAS mutations in circulating Tumor DNA by digital PCR in early stages of pancreatic cancer[J].Clin Chem,2016,62(11):1482.
[15] BAI H,MAO L,WANG H S,et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to IV non-small-cell lung cancer[J].J Clin Oncol,2009,27(16):2653-2659.
[16] GAJI B,STEVANOVI J,ŽELJKO RADULOVI,et al.Haplotype identification and detection of mitochondrial DNA heteroplasmy in Varroa destructor,mites using ARMS and PCR-RFLP methods[J].Exp Appl Acarol,2016,70(3):287-297.
[17] WANG W,SONG Z,ZHANG Y.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance[J].Cancer Med,2017,6(1):154-162.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 274443 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541